We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Argenx Picks Up Priority Review Voucher for $102 Million
Argenx Picks Up Priority Review Voucher for $102 Million
In a deal set to strengthen two different clinical research platforms, Bluebird Bio has sold one of its rare pediatric disease priority review vouchers (PRV) to the immunology company Argenx for $102 million.